![]() Shares of Sensei Biotherapeutics are up 4% in pre-market trade on Wednesday.įor More Such Health News, visit . Sensei Biotherapeutics (NASDAQ: SNSE) is an immuno-oncology company that focuses on overturning the body’s tolerance of cancer cells and directing its defenses against them. Sensei Biotherapeutics plans to file an IND during the first half of 2023. The company noted that experiments in a mouse tumor model showed a significant increase in the production of anti-tumor CD8+ T cells among animals treated with a combination of SNS-101 and anti-PD-1 antibodies compared with PD-1 alone. SNS-101 also displayed a favorable pharmacokinetic profile in non-human primates compared with a clinical-stage, pH-independent VISTA antibody. The company said these preclinical data show that its conditionally active, pH-selective antibody successfully overcomes pharmacokinetic issues associated with targeting the VISTA immune checkpoint, including target-mediated drug disposition and cytokine release syndrome, in these models. Our proprietary ImmunoPhage platform is a powerful, self-adjuvanted and highly differentiated immunotherapy approach that is designed to utilize.Price range: 19.00 - 19. ![]() (SNSE) reported preliminary preclinical data from mouse and non-human primate studies of SNS-101, a monoclonal antibody targeting the immune checkpoint VISTA. “With experienced management and scientific teams, Sensei is well positioned to become a leader in next generation of immune-oncology therapeutics,” Cambrian Biopharma CEO James Peyer said in a statement.(RTTNews) - Sensei Biotherapeutics, Inc. The company developing novel biologics therapies targeting key components of the immune system for the treatment of cancers of unmet need. This initial data from 9 patients provides us with the rationale to continue exploring its safety and efficacy in 1 st and 2 nd line SCCHN patients.įuture Ventures, Christian Angermayer’s Apeiron Investment Group, and Presight Ventures also chipped in to the round. Sensei Biotherapeutics is a clinical-stage biotechnology company specializing in the field of next-generation cancer immunotherapies. To date, we have observed promising clinical activity that is correlated with immune response for SNS-301, including a partial response in a patient with PD-L1-negative disease. “The approval of pembrolizumab is an exciting event for patients, but clearly there’s a lot of room for improvement,” Celebi said, citing a Keynote-012 study which showed Merck’s drug achieved an 18% overall response in patients with metastatic squamous cell carcinoma of the head and neck.ĬMO Marie-Louise Fjaellskog noted in a statement: One of 9 patients evaluated at the time had a partial response, with a tumor reduction of 43%, according to the company. And at ESMO, the biotech read out early data from a Phase I/II study of the candidate and Merck’s Keytruda for advanced head and neck cancer. (nasdaq: snse), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for. Last summer, Sensei joined forces with AstraZeneca to test SNS-301 in combination with Imfinzi in two Phase II trials across multiple solid tumors. 31, 2022 (globe newswire) - sensei biotherapeutics, inc. That includes SNS-401, a potential vaccine cocktail against Merkel cell carcinoma, and SNS-VISTA, an antibody-based therapeutic. ![]() It will also help ready the biotech’s earlier candidates for IND applications, which could come sometime in the next 12 to 18 months. It was led by Cambrian Biopharma and H&S Ventures, and will fund the Phase II development of SNS-301. The round, which the company is calling a Series AA, follows several seed rounds, Celebi said. ![]() “Right now we’re really focused on adding additional Phase II clinical and translational data to support SNS-301,” CEO John Celebi said. The Maryland-based biotech, formerly known as Panacea, is looking to expand Phase II trials for SNS-301, an engineered inactivated bacteriophage designed to “awaken” the immune system. Less than a month after offering a glimpse at early clinical data for its lead cancer immunotherapy at virtual ESMO, Sensei Biotherapeutics has reeled in $28.5 million to wade deeper into Phase II. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |